Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

Ohad Benjamini, Avichai Shimoni, MD, Michal Besser, PhD, Noga Shem-Tov, MD, Ivetta Danylesko, MD, Ronit Yerushalmi, MD, Drorit Grizim Merkel, MD, Tamar Tadmor, MD, David Lavie, MD, Riva Fineman, MD, Elad Jacobi, MD, Arnon Nagler, MD, Abraham Avigdor, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-138904

Published: 2020

Journal Articles

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Yishai Ofran, MD, Ronit Leiba, Dina Rosenberg, Israel Henig, MD, Dana Yehudai-Ofir, MD, Nuhad Haddad, MD, Riva Fineman, MD, Avraham Frisch, MD, Doaa Okasha, MD, Yariv Carasso, MD, Tsila Zuckerman, MD, Nurit Horesh, MD

Blood (2019) 134 (Supplement_1): 2603.

https://doi.org/10.1182/blood-2019-126553

Published: 2019

Journal Articles

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Yair Herishanu, MD, Adir Shaulov, MD, Riva Fineman, MD, Sandra Bašić-Kinda, MD, Ariel Aviv, MD, Ewa Wasik-Szczepanek, MD PhD, Ozren Jaksic, MD PhD, Mihnea Zdrenghea, MD, Uri Greenbaum, MD, Inga Mandac, MD, Martin Simkovic, MD PhD, Marta Morawska, MD, Ohad Benjamini, MD, Martin Spacek, MD, Anatoly Nemets, MD, Osnat Bairey, MD PhD, Andrea Visentin, MD, Rosa Ruchlemer, MD, Luca Laurenti, MD, Oana Stanca Ciocan, MD, Michael Doubek, MD PhD, Lev Shvidel, MD, Nagib Deli, MD, Fatima Miras Calvo, MD, Anne De Meûter, Maria Dimou, MD PhD, Francesca Romana Mauro, MD, Marta Coscia, MD PhD, Horia Bumbea, MD PhD, Szász Róbert, Tamar Tadmor, MD, Odit Gutwein, Massimo Gentile, Lydia Scarfo, MD, Alessandra Tedeschi, MD, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet Palomanes, MD, Sarit Assouline, MD, Maria Papaioannou, Andrei Breaster, MD, Luciano Levato, MD, Michael Gregor, MD, Gian Matteo Rigolin, MD, Javier Loscertales, MD, Angeles Medina Perez, MD, Marten R. Nijziel, MD PhD, Viola Maria Popov, MDPhDMSc, Rosa Collado, MD, Irma Slavutsky, Shai Levi, MSc, Aaron Polliack, MD, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 1766.

https://doi.org/10.1182/blood-2019-122309

Published: 2019

Journal Articles

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Tamar Tadmor, MD, Yair Herishanu, MD, Andrei Braester, MD, Osnat Bairey, MD, Ariel Aviv, Naomi Rahimi-Levene, MD, Riva Fineman, MD, Itai Levi, MD, Mona Yuklea, MD, Rosa Ruchlemer, MD, Lev Shvidel, MD, Aaron Polliack, MD

Blood (2018) 132 (Supplement 1): 5566.

https://doi.org/10.1182/blood-2018-99-111681

Published: 2018

Journal Articles

Prognosis of Patients with Standard- or Intermediate-Risk Acute Myeloid Leukemia Presenting with Residual Disease after One Induction Cycle Is Improved If Remission Is Achieved Following Re-Induction Given By Day 14 Compared to Second-Line Therapy Given 24-40 Days after Induction

Avraham Frisch, MD, Ronit Leiba, MSc, Chezi Ganzel, Tsila Zuckerman, MD, Nuhad Haddad, MD, Riva Fineman, MD, Yishai Ofran, MD

Blood (2016) 128 (22): 3999.

https://doi.org/10.1182/blood.V128.22.3999.3999

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation in Favorable Acute Myeloid Leukemia Is Associated with a Better Long-Term Prognosis: a Single Center Experience

Ofrat Beyar-Katz, MD, Israel Henig, MD, Dana Yehudai, MD, Nov Yuval, MSc, Riva Fineman, MD, Nuhad Haddad, MD, Yishai Ofran, MD, Jacob M. Rowe, MD, Tsila Zuckerman, MD

Blood (2016) 128 (22): 5819.

https://doi.org/10.1182/blood.V128.22.5819.5819

Published: 2016

Journal Articles

Semaphorin 3A Expression on Donor and Recipient Regulatory Cells: A Novel Pre-Transplant Biomarker Predicting the Development of Acute Graft-Versus-Host Disease

Zahava Vadas, MD PhD, Eti Ganon-Elazar, PhD, Yuval Nov, PhD, Israel Henig, MD, Dina Attias, MD, Nuhad Haddad, MD, Riva Fineman, MD, Jacob M. Rowe, MD, Tsila Zuckerman, MD

Blood (2014) 124 (21): 3935.

https://doi.org/10.1182/blood.V124.21.3935.3935

Published: 2014

Journal Articles

Cancer Registries Often Underestimate the True Incidence of CLL

Rosa Ruchlemer, MD, Miri Zatlawi, Yehudit Fishler, Rita Dichtiar, Barbara Silverman, MD MPH, Ariel Aviv, MD, Ariella Arad, MD, Osnat Bairey, MD, Ohad Binyamini, MD, Andre Braester, MD, Riva Fineman, MD, Neta Goldshmidt, MD, Yair Herishanu, MD, Naomi Rahimi-Levene, Lev Shvidel, MD, Tamar Tadmor, MD, Mona Yuklea, MD, Aaron Polliack, MD, Lital Keinan-Boker, MD PhD MPH

Blood (2014) 124 (21): 5646.

https://doi.org/10.1182/blood.V124.21.5646.5646

Published: 2014

Journal Articles

Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience

Yair Herishanu, MD, Neta Goldschmidt, MD, Osnat Bairey, MD, Rosa Ruchlemer, MD, Riva Fineman, MD, Naomi Rahimi-Levene, Lev Shvidel, MD, Tamar Tadmor, MD, Ariel Aviv, MD, Andrei Braester, MD, Erel Joffe, MDMSc, Aaron Polliack, MD

Blood (2014) 124 (21): 5659.

https://doi.org/10.1182/blood.V124.21.5659.5659

Published: 2014

Journal Articles

Stable Blood Group Chimerism in Recipients of ABO Incompatible Allogeneic Stem Cell Transplantation

Ami Glik, MD, Lilach Bonstein, PhD, Nardeen Atwah, BSc, Eti Ganon-Elazar, PhD, Israel Henig, MD, Nuhad Haddad, MD, Riva Fineman, MD, Jacob M. Rowe, MD, Tsila Zuckerman, MD

Blood (2014) 124 (21): 1553.

https://doi.org/10.1182/blood.V124.21.1553.1553

Published: 2014

Journal Articles

Richter’s Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors

Tamar Tadmor, MD, Riva Fineman, MD, Lev Shvidel, Osnat Bairey, MD, Neta Goldschmidt, MD, Rosa Ruchlemer, Naomi Rahimi Rachimi, MD, Yair Herishanu, MD, Mona Yuklea, MD,, Ariela Arad, MD, Ariel Aviv, MD, Aaron Polliack, MD

Blood (2013) 122 (21): 5281.

https://doi.org/10.1182/blood.V122.21.5281.5281

Published: 2013

Journal Articles

Post-Engraftment Persistent Leukocytosis May Be An Independent Poor Prognostic Factor in Allogeneic Stem Cell Transplant Patients

Nuhad Haddad, MD, Riva Fineman, MD, Tsila Zuckerman, MD, Jacob M. Rowe, MD

Blood (2011) 118 (21): 4574.

https://doi.org/10.1182/blood.V118.21.4574.4574

Published: 2011

Journal Articles

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Eldad Dann, MD, Rachel Bar-Shalom, MD, Ada Tamir, PhD, Menachem Ben-Shachar, MD, Irit Avivi, MD, Tsila Zuckerman, MD, Nuhad Haddad, MD, Hanna Rosenbaum, MD, Riva Fineman, MD, Odelia Goor, MD, Diana Libster, MD, Zeev Blumenfeld, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2009) 114 (22): 1552.

https://doi.org/10.1182/blood.V114.22.1552.1552

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation (ASCT) in CML with Partial T-Cell Depletion, No Prophylaxis for Graft-Versus-Host Disease (GvHD) and Preemptive DLI for Patients with Post-Transplant Minimal Residual Disease (MRD): An Alternative Approach in CML Transplantation with Low Morbidity and Long Term Disease Free Survival.

Tsila Zuckerman, MD, Tamar Katz, PhD, Nuhad Haddad, MD, Riva Fineman, MD, Irit Avivi, MD, Eldad J. Dann, MD, Dvora Sahar, PhD, Ana Oliven, MSc, Ety Hertz, Yishay Ofran, MD, Luiza Akria, MD, Michal Markovitz, Tal Faibish, MSc, Jacob M. Rowe, MD

Blood (2006) 108 (11): 318.

https://doi.org/10.1182/blood.V108.11.318.318

Published: 2006

Journal Articles

Extracorporeal Photopheresis (ECP) for Acute and Chronic GVHD, a Report of 56 Patients Treated in a Single Institution.

Eldad J. Dann, MD, Alla Badian, MD, Tselestina Stravets, MD, Elena Kertsman, Irit Avivi, MD, Ronit Elhasid, MD, Nuhad Haddad, MD, Riva Fineman, MD, Tsila Zuckerman, MD, Ana Oliven, Lilah Bonstein, PhD, Jacob M. Rowe, MD

Blood (2004) 104 (11): 5106.

https://doi.org/10.1182/blood.V104.11.5106.5106

Published: 2004

Journal Articles

CA-125 as a Marker for the Early Diagnosis of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation.

Tsila Zuckerman, MD, Shani Ben Harush, MD, Irit Avivi, MD, Israel Gavish, MD, Nuhad Haddad, MD, Riva Fineman, MD, Eldad Dann, MD, Ron Hoffman, MD, Benjamin Brenner, MD, Jacob M. Rowe, MD, Eli Zuckerman, MD

Blood (2004) 104 (11): 1138.

https://doi.org/10.1182/blood.V104.11.1138.1138

Published: 2004

NARROW

Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Prognosis of Patients with Standard- or Intermediate-Risk Acute Myeloid Leukemia Presenting with Residual Disease after One Induction Cycle Is Improved If Remission Is Achieved Following Re-Induction Given By Day 14 Compared to Second-Line Therapy Given 24-40 Days after Induction

Autologous Stem Cell Transplantation in Favorable Acute Myeloid Leukemia Is Associated with a Better Long-Term Prognosis: a Single Center Experience

Semaphorin 3A Expression on Donor and Recipient Regulatory Cells: A Novel Pre-Transplant Biomarker Predicting the Development of Acute Graft-Versus-Host Disease

Cancer Registries Often Underestimate the True Incidence of CLL

Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience

Stable Blood Group Chimerism in Recipients of ABO Incompatible Allogeneic Stem Cell Transplantation

Richter’s Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors

Post-Engraftment Persistent Leukocytosis May Be An Independent Poor Prognostic Factor in Allogeneic Stem Cell Transplant Patients

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Extracorporeal Photopheresis (ECP) for Acute and Chronic GVHD, a Report of 56 Patients Treated in a Single Institution.

CA-125 as a Marker for the Early Diagnosis of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only